Skip to content

Study · Systematic review · 2026

3 results

Evaluating bowel obstruction and ileus events in patients on GLP-1 receptor agonists: a systematic review and meta-analysis.

Alfehaid L, Alyami M, Almohareb S, Alshaya O, Almutairi A

Expert opinion on drug safety22 Feb 2025Cited by 4 (Europe PMC)

PMID39964295 (opens in a new tab)DOI10.1080/14740338.2025.2465870 (opens in a new tab)PepBankPUB-39964295
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanSystematic reviewSafety outcome

    In a medication subgroup analysis, liraglutide was associated with higher bowel obstruction or ileus risk.

    In plain wordsIn adults, liraglutide was linked to higher bowel obstruction or ileus risk in a medication subgroup analysis.

    Peptide
    Liraglutide
    Outcome
    IncreaseBowel obstruction or ileus
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    OR
    3
    liraglutide
    95% CI
    2.03 to 4.45
    liraglutide

    Source sentences

    Summary
    A subgroup analysis by specific medication revealed that liraglutide was associated with a significantly high risk of bowel obstruction or ileus (OR 3.0, 95% CI 2.03-4.45; I2 = 0%).
    1 context sentence
    Summary · context
    We searched databases, including Medline, Embase, and Cochrane, for studies on adult patients treated with GLP-1 RA. We included randomized control trials (RCT), cohort, case-control studies, and case reports.

Studies that did not test the peptide alone2

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 02HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In adults, pooled GLP-1 receptor agonists including liraglutide did not show a significant increase in bowel obstruction or ileus versus controls (OR 1.95, 95% CI 0.43-8.79; I2 = 94%).

    In plain wordsIn adults, pooled GLP-1 drugs including liraglutide did not show a significant increase in bowel obstruction or ileus versus controls.

    Peptide
    Liraglutide
    Outcome
    No significant changeBowel obstruction or ileus
    Study

    n = 550,426

    Comparator
    Controls
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Measurements

    OR
    1.95
    GLP-1 RA versus controls
    95% CI
    0.43 to 8.79
    GLP-1 RA versus controls

    Source sentences

    Summary
    The use of GLP-1 RA did not show an incremental risk of bowel obstruction or ileus compared to controls (OR 1.95, 95% CI 0.43-8.79).
    3 context sentences
    Summary · context
    However, the studies had high heterogeneity (I2 = 94%).
    Summary · context
    We searched databases, including Medline, Embase, and Cochrane, for studies on adult patients treated with GLP-1 RA. We included randomized control trials (RCT), cohort, case-control studies, and case reports.
    Summary · context
    The meta-analysis included 6 studies with a combined total of 550,426 participants.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 03HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In adults, pooled GLP-1 receptor agonists including semaglutide did not show a significant increase in bowel obstruction or ileus versus controls (OR 1.95, 95% CI 0.43-8.79; I2 = 94%).

    In plain wordsIn adults, pooled GLP-1 drugs including semaglutide did not show a significant increase in bowel obstruction or ileus versus controls.

    Peptide
    Semaglutide
    Outcome
    No significant changeBowel obstruction or ileus
    Study

    n = 550,426

    Comparator
    Controls
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Measurements

    OR
    1.95
    GLP-1 RA versus controls
    95% CI
    0.43 to 8.79
    GLP-1 RA versus controls

    Source sentences

    Summary
    The use of GLP-1 RA did not show an incremental risk of bowel obstruction or ileus compared to controls (OR 1.95, 95% CI 0.43-8.79).
    3 context sentences
    Summary · context
    However, the studies had high heterogeneity (I2 = 94%).
    Summary · context
    We searched databases, including Medline, Embase, and Cochrane, for studies on adult patients treated with GLP-1 RA. We included randomized control trials (RCT), cohort, case-control studies, and case reports.
    Summary · context
    The meta-analysis included 6 studies with a combined total of 550,426 participants.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.